These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8627865)

  • 41. Leuprolide with flutamide for complete androgen ablation: therapeutic alternative for advanced prostatic cancer (stage D2).
    Chime-Udeh E
    Conn Med; 1991 Sep; 55(9):526-8. PubMed ID: 1748007
    [No Abstract]   [Full Text] [Related]  

  • 42. Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer.
    Eastham JA; Sartor O
    J Urol; 1998 Mar; 159(3):990. PubMed ID: 9474206
    [No Abstract]   [Full Text] [Related]  

  • 43. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
    Fujii Y; Kawakami S; Masuda H; Kobayashi T; Hyochi N; Kageyama Y; Kihara K
    BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
    Shulman MJ; Karam JA; Benaim EA
    Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Changes in free and free-to-total prostate specific antigen after androgen deprivation or chemotherapy in patients with advanced prostate cancer.
    Berruti A; Dogliotti L; Fasolis G; Mosca A; Tarabuzzi R; Torta M; Mari M; Fontana D; Angeli A
    J Urol; 1999 Jan; 161(1):176-81. PubMed ID: 10037393
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Basic and clinical characteristics of flutamide].
    Suzuki K; Nakazato H; Kurokawa K; Yamanaka H
    Nihon Rinsho; 2000 Jul; 58 Suppl():211-5. PubMed ID: 11022716
    [No Abstract]   [Full Text] [Related]  

  • 47. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
    Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Androgen deprivation therapy for prostate cancer.
    Bahnson R
    J Urol; 2007 Oct; 178(4 Pt 1):1148. PubMed ID: 17698142
    [No Abstract]   [Full Text] [Related]  

  • 49. [The antiandrogen withdrawal syndrome: decrease in prostate specific antigen serum levels after withdrawal of antiandrogens].
    Hornák M; Bárdos A; Goncalves F
    Rozhl Chir; 1997 Sep; 76(9):435-7. PubMed ID: 9471771
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer.
    Pitts WR
    BJU Int; 2004 May; 93(7):1119-20. PubMed ID: 15142186
    [No Abstract]   [Full Text] [Related]  

  • 51. Survival analyses overview in hormone-refractory prostate cancer clinical trials in the prostate-specific antigen era.
    Sartor O
    Clin Genitourin Cancer; 2007 Dec; 5(7):420-1. PubMed ID: 18272022
    [No Abstract]   [Full Text] [Related]  

  • 52. Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.
    Spitz IM; Chertin B; Fridmans A; Farkas A; Belanger A; Hartman H; Labrie F
    Prostate Cancer Prostatic Dis; 2009; 12(1):100-3. PubMed ID: 18574491
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome.
    Kelly WK; Scher HI
    J Urol; 1993 Mar; 149(3):607-9. PubMed ID: 7679759
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor inhibition in prostate cancer cells.
    Kai L; Levenson AS
    Anticancer Res; 2011 Oct; 31(10):3323-30. PubMed ID: 21965742
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease.
    Spahn M; Briganti A; Capitanio U; Kneitz B; Gontero P; Karnes JR; Schubert M; Montorsi F; Scholz CJ; Bader P; van Poppel H; Joniau S;
    J Urol; 2012 Jul; 188(1):84-90. PubMed ID: 22578727
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm.
    Small EJ; Vogelzang NJ
    J Clin Oncol; 1997 Jan; 15(1):382-8. PubMed ID: 8996165
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy.
    Moul JW; Zlotta AR
    BJU Int; 2005 Feb; 95(3):285-90. PubMed ID: 15679779
    [No Abstract]   [Full Text] [Related]  

  • 59. A prospective randomized multicenter study of chlormadinone acetate versus flutamide in total androgen blockade for prostate cancer.
    Ozono S; Okajima E; Yamaguchi A; Yoshikawa M; Iwai A; Moriya A; Yoshida K; Samma S; Maruyama Y; Hirao Y
    Jpn J Clin Oncol; 2000 Sep; 30(9):389-96. PubMed ID: 11095136
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prostate cancer: an enzalutamide antiandrogen withdrawal syndrome.
    Phillips R
    Nat Rev Urol; 2014 Jul; 11(7):366. PubMed ID: 24960596
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.